Leukapheresis Market Size, Share, Trends and Forecast, 2032

Leukapheresis Market Insights

According to Market Research Store, the global Leukapheresis market size was valued at around USD 212.36 million in 2023 and is estimated to reach USD 510.65 million by 2032, to register a CAGR of approximately 10.24% in terms of revenue during the forecast period 2024-2032.

The Leukapheresis report provides a comprehensive analysis of the market, including its size, share, growth trends, revenue details, and other crucial information regarding the target market. It also covers the drivers, restraints, opportunities, and challenges till 2032.

To Get more Insights, Request a Free Sample

Global Leukapheresis Market: Overview

Leukapheresis is a medical procedure used to separate and remove white blood cells (leukocytes) from a patient's blood. It is a specialized type of apheresis where blood is drawn from the body, processed through a machine that filters out the white blood cells, and the remaining components—such as red blood cells, platelets, and plasma—are returned to the patient. Leukapheresis is commonly used to treat conditions involving an abnormally high white blood cell count, such as leukemia, and is also employed in the collection of white cells for research, stem cell transplantation, and cellular therapies like CAR-T cell treatment.

Key Highlights

• The Leukapheresis market is anticipated to grow at a CAGR of 10.24% during the forecast period.
• The global Leukapheresis market was estimated to be worth approximately USD 212.36 million in 2023 and is projected to reach a value of USD 510.65 million by 2032.
• The growth of the Leukapheresis market is being driven by rising incidences of blood cancers, increasing adoption of cellular immunotherapies, and growing demand for leukocyte collection in research and clinical applications.
• Based on the product type, the leukapheresis disposables segment is growing at a high rate and is projected to dominate the market.
• On the basis of application, the research applications segment is projected to swipe the largest market share.
• In terms of end-user, the blood component providers & blood centers segment is expected to dominate the market.
• By region, North America is expected to dominate the global market during the forecast period.

Leukapheresis Market: Dynamics

Key Growth Drivers:

• Rising Prevalence of Hematologic Disorders: Increasing cases of leukemia, lymphoma, and other blood cancers are boosting the demand for leukapheresis in both treatment and research.
• Growing Adoption of Cell-Based Therapies: The use of leukapheresis in CAR-T cell and stem cell therapy is expanding rapidly, especially for personalized and precision medicine.
• Advancements in Apheresis Technologies: Technological improvements in leukapheresis devices and procedures have enhanced efficiency, safety, and patient comfort, encouraging wider adoption.
• Increased Investment in Immunotherapy Research: Growing funding and clinical trials in immunotherapies are driving the use of leukapheresis for cell collection and development purposes.

Restraints:

• High Cost of Procedures and Equipment: Leukapheresis involves expensive devices, consumables, and maintenance, limiting its accessibility in cost-sensitive markets.
• Limited Availability of Skilled Professionals: The procedure requires trained healthcare personnel, which is lacking in several developing and underdeveloped regions.
• Complex Regulatory Approval Process: Stringent and lengthy regulatory procedures for cell therapies that involve leukapheresis can delay product development and market entry.

Opportunities:

• Expansion of Clinical Applications: Leukapheresis is increasingly being explored for autoimmune diseases and other chronic conditions beyond oncology.
• Emerging Markets in Asia and Latin America: Rapid healthcare infrastructure development and rising awareness offer untapped growth potential in these regions.
• Partnerships and Collaborations: Collaborations between research institutes and biotech firms are expected to accelerate product innovation and global reach.

Challenges:

• Logistical and Infrastructure Barriers: Efficient execution of leukapheresis requires specialized facilities, which are not widely available in rural or resource-limited areas.
• Patient Compliance and Awareness: Limited understanding of leukapheresis procedures and benefits among patients can hinder treatment acceptance and adoption.
• Variability in Clinical Outcomes: Differences in patient responses and cell quality post-procedure may affect treatment consistency and reliability.

Leukapheresis Market: Report Scope

This report thoroughly analyzes the Leukapheresis Market, exploring its historical trends, current state, and future projections. The market estimates presented result from a robust research methodology, incorporating primary research, secondary sources, and expert opinions. These estimates are influenced by the prevailing market dynamics as well as key economic, social, and political factors. Furthermore, the report considers the impact of regulations, government expenditures, and advancements in research and development on the market. Both positive and negative shifts are evaluated to ensure a comprehensive and accurate market outlook.

Leukapheresis Market: Segmentation Insights

The global Leukapheresis market is divided by product type, application, end-user, and region.

Segmentation Insights by Product Type

Based on product type, the global Leukapheresis market is divided into leukapheresis disposables and leukapheresis devices.

In the leukapheresis market, leukapheresis disposables represent the most dominant segment by product type. This dominance is attributed to their recurring use in every procedure, including tubing sets, filters, and separation kits, which ensures a continuous demand. Disposables are essential for maintaining sterility and preventing cross-contamination, making them critical components in both therapeutic and research applications. The rising volume of leukapheresis procedures in hospitals, blood centers, and clinical trials significantly drives the growth of this segment. Moreover, the growing demand for personalized medicine and cell-based therapies further boosts the need for high-quality, single-use disposable components.

On the other hand, leukapheresis devices form the smaller yet steadily growing segment. These are capital-intensive, high-precision machines used to perform the actual separation of white blood cells from whole blood. Although the demand for devices is limited by their one-time purchase nature and high upfront cost, continuous advancements in automation, portability, and efficiency are enhancing their market appeal. The growth in this segment is supported by increasing installations in emerging healthcare markets and rising investments in advanced apheresis technologies. However, compared to disposables, the frequency of replacement and purchase remains significantly lower, keeping this segment in the second position.

Segmentation Insights by Application

On the basis of application, the global Leukapheresis market is bifurcated into research applications and therapeutic applications.

In the leukapheresis market, research applications constitute the most dominant segment by application. This dominance is largely driven by the rising focus on cell-based research, including immunotherapy, regenerative medicine, and stem cell studies. Leukapheresis is widely used in academic and pharmaceutical research settings to isolate white blood cells for various experimental and clinical trial purposes, especially in the development of CAR-T cell therapies and other personalized treatment strategies. The increasing number of clinical trials and growing investment in biotechnology and cancer research further boost the demand in this segment, making it the primary application area globally.

Therapeutic applications, while growing steadily, represent the secondary segment. This includes the use of leukapheresis as a treatment for conditions such as leukemia, autoimmune disorders, and other blood-related illnesses. In clinical practice, leukapheresis is employed to rapidly reduce high white blood cell counts in critical conditions and to prepare patients for cell-based therapies. Though this segment is expected to grow with the expanding application of immunotherapies and advanced treatment protocols, its market share remains lower than research applications due to fewer procedures performed per patient and limited accessibility in some regions.

Segmentation Insights by End-User

Based on end-user, the global Leukapheresis market is divided into blood component providers & blood centers, pharmaceutical & biotechnology companies, academic & research institutes, and hospital & transfusion centers.

In the leukapheresis market, blood component providers & blood centers are the most dominant end-user segment. These facilities are the primary hubs for leukocyte collection and apheresis procedures, supporting both clinical and research requirements. Their consistent need for leukapheresis disposables and devices, especially for large-scale donor collections and component separation, drives substantial demand. Additionally, the increasing use of leukapheresis in stem cell and platelet collections contributes to their leading position in the market.

Pharmaceutical and biotechnology companies form the second-largest segment, driven by the rising development of cell-based therapies, particularly in oncology and immunotherapy. These companies utilize leukapheresis in preclinical and clinical stages to extract cells for drug development, CAR-T therapies, and personalized medicine. Their high investment capabilities and strong research focus contribute to robust market demand.

Academic and research institutes follow, leveraging leukapheresis for investigative purposes, including studies on immune responses, cell biology, and new therapeutic approaches. While they generate moderate demand compared to industry players, their role is growing with the surge in public and private funding for cell and gene therapy research.

Hospitals and transfusion centers represent the smallest yet crucial segment. These facilities use leukapheresis in therapeutic settings, especially for patients with leukostasis, leukemia, or other hematologic conditions. Despite their importance in patient care, the limited frequency of procedures and high operational costs contribute to a smaller market share compared to other end-user groups.

Leukapheresis Market: Regional Insights

• North America is expected to dominates the global market

North America leads the leukapheresis market, driven by the high prevalence of hematologic cancers, widespread use of CAR-T cell therapies, and the presence of advanced healthcare infrastructure. The region benefits from strong research funding, early adoption of innovative technologies, and a growing number of clinical trials involving leukapheresis. The United States, in particular, plays a major role due to the presence of key biotechnology and pharmaceutical companies, as well as established regulatory frameworks that support cell therapy development and implementation.

Europe follows as the second most dominant region in the leukapheresis market, supported by an increasing number of cancer cases, rising investments in regenerative medicine, and a growing network of biobanks and cell therapy research institutions. Countries like Germany, the UK, and France have been at the forefront in adopting advanced apheresis technologies and integrating leukapheresis into personalized treatment approaches. Regulatory harmonization across the European Union also aids in the cross-border collaboration and development of leukapheresis-based therapies.

Asia Pacific is an emerging region showing rapid growth in the leukapheresis market due to expanding healthcare infrastructure, growing awareness of cell-based therapies, and increasing cancer incidence across countries such as China, Japan, South Korea, and India. Government initiatives to boost biotech research, along with the establishment of cell therapy manufacturing facilities, have fueled market development. Additionally, the rising demand for advanced treatment options and increasing participation in international clinical trials are enhancing the region’s market potential.

Latin America holds a smaller but gradually expanding share of the leukapheresis market, supported by improvements in healthcare access and infrastructure. Countries like Brazil and Mexico are beginning to invest more in cancer research and advanced therapeutic procedures, although the adoption rate of leukapheresis technologies remains relatively moderate. Limited funding and healthcare disparities still pose challenges, but ongoing collaborations with global healthcare organizations are helping to improve diagnostic and treatment capabilities.

Middle East and Africa represents the least dominant segment in the leukapheresis market, primarily due to limited access to advanced medical technologies, lower awareness of cell-based therapies, and insufficient healthcare infrastructure in many areas. However, in wealthier Gulf nations such as the UAE and Saudi Arabia, investments in modern healthcare facilities and international medical partnerships are slowly paving the way for future market development. Broader adoption across the region remains constrained by economic and logistical barriers.

Leukapheresis Market: Competitive Landscape

The report provides an in-depth analysis of companies operating in the Leukapheresis market, including their geographic presence, business strategies, product offerings, market share, and recent developments. This analysis helps to understand market competition.

Some of the major players in the global Leukapheresis market include:

• Asahi Kasei Medical Co. Ltd.
• Haemonetics Corporation
• Fresenius SE & Co. KGaA
• Terumo BCT Inc.
• Miltenyi Biotec
• Macopharma SA
• Guangzhou Daji Medical Science and Technology Co. Ltd.
• PuriBlood Medical Co. Ltd.
• MEDICA S.p.A
• Beijing ZKSK Technology Co. Ltd.

The global Leukapheresis market is segmented as follows:

By Product Type

• Leukapheresis Disposables
• Leukapheresis Devices

By Application

• Research Applications
• Therapeutic Applications

By End-User

• Blood Component Providers and Blood Centers
• Pharmaceutical and Biotechnology Companies
• Academic and Research Institutes
• Hospital and Transfusion Centers

By Region

• North America
  • U.S.
  • Canada
• Europe
  • U.K.
  • France
  • Germany
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• The Middle East and Africa
  • GCC Countries
  • South Africa
  • Rest of Middle East Africa

Frequently Asked Questions